WO2006121656A3 - Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease - Google Patents

Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease Download PDF

Info

Publication number
WO2006121656A3
WO2006121656A3 PCT/US2006/016481 US2006016481W WO2006121656A3 WO 2006121656 A3 WO2006121656 A3 WO 2006121656A3 US 2006016481 W US2006016481 W US 2006016481W WO 2006121656 A3 WO2006121656 A3 WO 2006121656A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
alzheimer
disease
treatment
immunogenic fragment
Prior art date
Application number
PCT/US2006/016481
Other languages
French (fr)
Other versions
WO2006121656A2 (en
Inventor
Victor M Garsky
Joseph G Joyce
Paul M Keller
Gene Kinney
Xiaoping Liang
John W Shiver
Original Assignee
Merck & Co Inc
Victor M Garsky
Joseph G Joyce
Paul M Keller
Gene Kinney
Xiaoping Liang
John W Shiver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ562434A priority Critical patent/NZ562434A/en
Priority to US11/919,897 priority patent/US7850973B2/en
Application filed by Merck & Co Inc, Victor M Garsky, Joseph G Joyce, Paul M Keller, Gene Kinney, Xiaoping Liang, John W Shiver filed Critical Merck & Co Inc
Priority to EP06751930A priority patent/EP1879613B1/en
Priority to CN2006800153890A priority patent/CN101171031B/en
Priority to CA002607868A priority patent/CA2607868A1/en
Priority to MX2007013825A priority patent/MX2007013825A/en
Priority to JP2008510087A priority patent/JP2008540417A/en
Priority to AU2006246382A priority patent/AU2006246382A1/en
Priority to AT06751930T priority patent/ATE535252T1/en
Priority to BRPI0610093-7A priority patent/BRPI0610093A2/en
Publication of WO2006121656A2 publication Critical patent/WO2006121656A2/en
Publication of WO2006121656A3 publication Critical patent/WO2006121656A3/en
Priority to ZA2007/08635A priority patent/ZA200708635B/en
Priority to IL186793A priority patent/IL186793A0/en
Priority to NO20076239A priority patent/NO20076239L/en
Priority to US12/907,493 priority patent/US20110052611A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Abstract

The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer’s disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.
PCT/US2006/016481 2005-05-05 2006-05-01 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease WO2006121656A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AT06751930T ATE535252T1 (en) 2005-05-05 2006-05-01 PEPTIDE CONJUGATE COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE
AU2006246382A AU2006246382A1 (en) 2005-05-05 2006-05-01 Peptide conjugate compositions and methods for the prevention and treatment of Alzheimer's disease
EP06751930A EP1879613B1 (en) 2005-05-05 2006-05-01 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
US11/919,897 US7850973B2 (en) 2005-05-05 2006-05-01 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
CA002607868A CA2607868A1 (en) 2005-05-05 2006-05-01 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
MX2007013825A MX2007013825A (en) 2005-05-05 2006-05-01 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease.
BRPI0610093-7A BRPI0610093A2 (en) 2005-05-05 2006-05-01 pharmaceutical composition, and method for preventing or treating a disease associated with alpha-beta amyloid deposits in a patient's brain
NZ562434A NZ562434A (en) 2005-05-05 2006-05-01 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
CN2006800153890A CN101171031B (en) 2005-05-05 2006-05-01 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
JP2008510087A JP2008540417A (en) 2005-05-05 2006-05-01 Peptide conjugate compositions and methods for prevention and treatment of Alzheimer's disease
ZA2007/08635A ZA200708635B (en) 2005-05-05 2007-10-10 Peptide conjugate compositions and methods for the prevention and treatment of alzheimers disease
IL186793A IL186793A0 (en) 2005-05-05 2007-10-18 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
NO20076239A NO20076239L (en) 2005-05-05 2007-12-04 Peptide conjugate preparations and methods for the prevention and treatment of Alzheimer's disease
US12/907,493 US20110052611A1 (en) 2005-05-05 2010-11-08 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67788605P 2005-05-05 2005-05-05
US60/677,886 2005-05-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/907,493 Division US20110052611A1 (en) 2005-05-05 2010-11-08 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
WO2006121656A2 WO2006121656A2 (en) 2006-11-16
WO2006121656A3 true WO2006121656A3 (en) 2007-01-04

Family

ID=37019042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/016481 WO2006121656A2 (en) 2005-05-05 2006-05-01 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease

Country Status (16)

Country Link
US (2) US7850973B2 (en)
EP (2) EP1879613B1 (en)
JP (1) JP2008540417A (en)
KR (1) KR20080005260A (en)
CN (1) CN101171031B (en)
AT (1) ATE535252T1 (en)
AU (1) AU2006246382A1 (en)
BR (1) BRPI0610093A2 (en)
CA (1) CA2607868A1 (en)
IL (1) IL186793A0 (en)
MX (1) MX2007013825A (en)
NO (1) NO20076239L (en)
NZ (1) NZ562434A (en)
RU (1) RU2406529C2 (en)
WO (1) WO2006121656A2 (en)
ZA (1) ZA200708635B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
CA2637472A1 (en) 2005-11-30 2007-06-07 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PE20090329A1 (en) * 2007-05-30 2009-03-27 Abbott Lab HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
KR101600095B1 (en) * 2007-06-12 2016-03-07 에이씨 이뮨 에스.에이. Monoclonal anti beta amyloid antibody
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
EP2020602A1 (en) * 2007-08-02 2009-02-04 Araclon Biotech High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
ITMI20071975A1 (en) * 2007-10-12 2009-04-13 Fond I R C C S Istituto Neur O PRODUCTS AND THEIR USE FOR DIAGNOSIS PREVENTION AND-OR TREATMENT OF HUMAN PATHOLOGIES E-O ANIMALS CHARACTERIZED BY THE ANOMALA DEPOSITION OF B-AMYLOID E-O SIMILAMYLOID SUBSTANCE IN HUMAN ORGANS AND TESSTUI E-O ANIMALS AND SCREENING METHOD FOR DETERMINATION
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US8586706B2 (en) 2007-10-25 2013-11-19 Kagoshima University Peptide vaccine using mimic molecules of amyloid β peptide
NZ590324A (en) * 2008-07-01 2012-08-31 Nederlanden Staat Vaccine against amyloid folding intermediate
CN102089000A (en) * 2008-07-08 2011-06-08 默沙东公司 Vaccine for the treatment of alzheimer's disease
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2344545A4 (en) * 2008-10-06 2012-10-03 Commw Scient Ind Res Org Amyloid-beta peptide crystal structure
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
CN106390107B (en) * 2009-06-10 2019-12-31 纽约大学 Immune targeting of pathological TAU proteins
EP2538982A4 (en) 2010-02-25 2016-02-17 Janssen Alzheimer Immunotherap Pet monitoring of ab-directed immunotherapy
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
WO2012072611A1 (en) * 2010-11-29 2012-06-07 Philipps-Universität Marburg SYNTHETIC LIGANDS FOR HUMAN ANTI-Aβ ANTIBODIES
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
WO2013059322A2 (en) * 2011-10-17 2013-04-25 Lawrence Steinman Amyloid beta peptide as a therapy for inflammation
JP2017513849A (en) * 2014-04-15 2017-06-01 グリフィス・ユニバーシティＧｒｉｆｆｉｔｈ Ｕｎｉｖｅｒｓｉｔｙ Group A Streptococcus vaccine
EP3166688A4 (en) 2014-07-08 2017-12-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
US10988528B2 (en) 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
ES2571055B1 (en) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Amyloid conjugate and its uses and procedures
KR20180134373A (en) * 2016-04-14 2018-12-18 타오 헬스 라이프 파마 가부시키가이샤 An amylose ferroide (ASPD) type structure and a pharmaceutical composition
KR101898623B1 (en) 2016-11-10 2018-09-13 주식회사 브레인숲 Paper toy brock
EP3700556A2 (en) 2017-10-25 2020-09-02 Janssen Pharmaceuticals, Inc. Compositions of phosphorylated tau peptides and uses thereof
RU2679080C1 (en) * 2018-04-17 2019-02-05 Александр Олегович Морозов Peptide and method of treatment of alzheimer's disease
RU2679059C1 (en) * 2018-04-17 2019-02-05 Александр Олегович Морозов Peptide and method of treatment of alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157117A1 (en) * 2001-08-20 2003-08-21 Rasmussen Peter Birk Novel method for down-regulation of amyloid
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494808A (en) 1994-09-15 1996-02-27 Merck & Co., Inc. Defined medium OMPC fermentation process
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP3854481B2 (en) * 2000-11-17 2006-12-06 三菱重工業株式会社 Wet flue gas desulfurization apparatus and wet flue gas desulfurization method
WO2003000719A2 (en) * 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
SG149013A1 (en) * 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157117A1 (en) * 2001-08-20 2003-08-21 Rasmussen Peter Birk Novel method for down-regulation of amyloid
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AGADJANYAN M G ET AL: "PROTOTYPE ALZHEIMER'S DISEASE VACCINE USING THE IMMUNODOMINANT B CELL EPITOPE FROM BETA-AMYLOID AND PROMISCUOUS T CELL EPITOPE PAN HLA DR-BINDING PEPTIDE", JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 174, no. 3, February 2005 (2005-02-01), pages 1580 - 1586, XP008052934, ISSN: 0022-1767 *
CRIBBS D H ET AL: "ADJUVANT-DEPENDENT MODULATION OF TH1 AND TH2 RESPONSES TO IMMUNIZATION WITH BETA-AMYLOID", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 15, no. 4, April 2003 (2003-04-01), pages 505 - 514, XP009013327, ISSN: 0953-8178 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Also Published As

Publication number Publication date
US20110052611A1 (en) 2011-03-03
CN101171031B (en) 2011-09-28
US20090098155A1 (en) 2009-04-16
RU2406529C2 (en) 2010-12-20
IL186793A0 (en) 2008-02-09
EP1879613B1 (en) 2011-11-30
NO20076239L (en) 2008-01-30
EP2269633A1 (en) 2011-01-05
KR20080005260A (en) 2008-01-10
WO2006121656A2 (en) 2006-11-16
NZ562434A (en) 2010-04-30
CA2607868A1 (en) 2006-11-16
RU2007145052A (en) 2009-06-10
MX2007013825A (en) 2008-01-18
JP2008540417A (en) 2008-11-20
ZA200708635B (en) 2008-10-29
US7850973B2 (en) 2010-12-14
ATE535252T1 (en) 2011-12-15
AU2006246382A1 (en) 2006-11-16
BRPI0610093A2 (en) 2008-12-09
CN101171031A (en) 2008-04-30
EP1879613A2 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
WO2006121656A3 (en) Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
ES2407429T3 (en) Therapeutic Vaccine
WO2005072777A3 (en) Conjugates of amyloid proteins as vaccines for amyloid-related diseases
AR024074A1 (en) ABETA FRAGMENT JOINED WITH A BEARING PEPTIDE TO PREVENT OR TREAT DISEASES ASSOCIATED WITH ABETA AMILOID DEPOSITS, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND ITS USE IN THE PREPARATION OF MEDICINES.
MY158903A (en) Antibodies specific for the protofibril form of beta-amyloid protein
JP2008508859A5 (en)
JP2012506411A5 (en)
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
UA94734C2 (en) THERAPEUTIC ANTIBODIY WHICH BINDS TO b-AMYLOID PEPTIDE
NO20071267L (en) Prevention and treatment of synucleinopathic and amyloidogenic diseases
EA200601761A1 (en) COMPOSITIONS AS ADJUVANTS FOR STRENGTHENING IMMUNE RESPONSES TO VACCINES AND METHODS OF THEIR USE
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2004013172A3 (en) Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
RU2011120706A (en) VACCINE COMPOSITIONS CONTAINING MUTED PROTEIN BINDING FACTOR N
WO2005120558A3 (en) Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
WO2003090686A3 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
JP2009520758A5 (en)
JP2009505979A5 (en)
JP2017508006A5 (en)
WO2010016912A3 (en) Immunotherapeutic compositions for the treatment of alzheimer's disease
WO2006027300A3 (en) Carrier conjugates of gnrh-peptides
WO2008066626A3 (en) METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
CA2730686A1 (en) Anti-amyloid immunogenic compositions, methods and uses
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680015389.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 562434

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 186793

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006246382

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/013825

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008510087

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006751930

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2607868

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11919897

Country of ref document: US

Ref document number: 1020077025682

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006246382

Country of ref document: AU

Date of ref document: 20060501

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 9383/DELNP/2007

Country of ref document: IN

Ref document number: 2007145052

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0610093

Country of ref document: BR